Non-bacterial thrombotic endocarditis historical perspective: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Aisha Adigun (talk | contribs) |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The association between [[Thrombosis|thromboembotic events]] and [[malignancy]] was made by Armand Trousseau in the year 1865. In 1926, Dr. Benjamin Sacks and Dr. Emmanuel Libman published cases of "valvular masses" that were examined clinically and during [[autopsies]] and found to be free of all [[Microorganism|microorganisms]]. These masses were initially named "indeterminate [[endocarditis]]". | |||
==Historical Perspective== | ==Historical Perspective== | ||
===Discovery=== | ===Discovery=== | ||
* | *The association between [[Thrombosis|thromboembotic events]] and [[malignancy]] was made by Armand Trousseau in the year 1865.<ref>Trousseau A. Clinique médicale de l’Hôtel-Dieu de Paris. Paris: Ballière; 1865 </ref> | ||
*[[Non-bacterial thrombotic endocarditis]] (NBTE) was first discovered by Zeigler,<ref name="pmid3548296">{{cite journal |vauthors=Lopez JA, Ross RS, Fishbein MC, Siegel RJ |title=Nonbacterial thrombotic endocarditis: a review |journal=Am. Heart J. |volume=113 |issue=3 |pages=773–84 |date=March 1987 |pmid=3548296 |doi=10.1016/0002-8703(87)90719-8 |url=}}</ref> in 1888 following his identification of [[vegetation]] in cardiac valves associated with [[inflammatory states]]. | |||
*[ | *In 1926, Dr. Benjamin Sacks and Dr. Emmanuel Libman<ref>E Ziegler - Ver Kong Inn Med, 1888 - ci.nii.ac.jp </ref> published cases of "valvular masses" that were examined clinically and during autopsies and found to be free of all microorganisms. These masses were initially named "indeterminate endocarditis". | ||
*In 1936, The name non-bacterial thrombotic endocarditis was coined by Gross and Friedberg. <ref> GROSS L, FRIEDBERG CK. NONBACTERIAL THROMBOTIC ENDOCARDITIS: CLASSIFICATION AND GENERAL DESCRIPTION. Arch Intern Med (Chic). 1936;58(4):620–640. doi:10.1001/archinte.1936.00170140045004 </ref>. They postulated that the attachment of [[fibrin]] to [[cardiac valves]] is the cause of non-bacterial thrombotic endocarditis. | |||
*The | *In recent years it has been suggested that NBTE is a [[hypercoagulable state]] caused by a [[malignancy]] that leads to a surge in [[tumor necrosis factor]] and [[interleukin-1]], resulting in the formation of [[thrombi]].<ref> Schlittler LA, Dallagasperina VW, Schavinski C, Baggio AP, Lazaretti NS, Villaroel RU. Marantic endocarditis and adenocarcinoma of unknown primary site. Arq Bras Cardiol. 2011;96(4):e73–5 </ref> <br /> | ||
*In [ | *More recently, in addition to malignancies, NBTEs have been associated with infectious and autoimmune diseases and more recently, sepsis and burns.<ref name="pmid16244577">{{cite journal |vauthors=Wada H, Sase T, Yamaguchi M |title=Hypercoagulant states in malignant lymphoma |journal=Exp. Oncol. |volume=27 |issue=3 |pages=179–85 |date=September 2005 |pmid=16244577 |doi= |url=}}</ref><ref name="pmid3916476">{{cite journal |vauthors=Ferrans VJ, Rodríguez ER |title=Cardiovascular lesions in collagen-vascular diseases |journal=Heart Vessels Suppl |volume=1 |issue= |pages=256–61 |date=1985 |pmid=3916476 |doi=10.1007/BF02072405 |url=}}</ref><ref name="pmid998478">{{cite journal |vauthors=Deppisch LM, Fayemi AO |title=Non-bacterial thrombotic endocarditis: clinicopathologic correlations |journal=Am. Heart J. |volume=92 |issue=6 |pages=723–9 |date=December 1976 |pmid=998478 |doi=10.1016/s0002-8703(76)80008-7 |url=}}</ref> | ||
=== | |||
==References== | ==References== | ||
Latest revision as of 21:33, 22 August 2020
|
non-bacterial thrombotic endocarditis |
|
Differentiating non-bacterial thrombotic endocarditis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Non-bacterial thrombotic endocarditis historical perspective On the Web |
|
American Roentgen Ray Society Images of Non-bacterial thrombotic endocarditis historical perspective |
|
FDA on Non-bacterial thrombotic endocarditis historical perspective |
|
CDC on Non-bacterial thrombotic endocarditis historical perspective |
|
Non-bacterial thrombotic endocarditis historical perspective in the news |
|
Blogs on Non-bacterial thrombotic endocarditis historical perspective |
|
Risk calculators and risk factors for Non-bacterial thrombotic endocarditis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]
Overview
The association between thromboembotic events and malignancy was made by Armand Trousseau in the year 1865. In 1926, Dr. Benjamin Sacks and Dr. Emmanuel Libman published cases of "valvular masses" that were examined clinically and during autopsies and found to be free of all microorganisms. These masses were initially named "indeterminate endocarditis".
Historical Perspective
Discovery
- The association between thromboembotic events and malignancy was made by Armand Trousseau in the year 1865.[1]
- Non-bacterial thrombotic endocarditis (NBTE) was first discovered by Zeigler,[2] in 1888 following his identification of vegetation in cardiac valves associated with inflammatory states.
- In 1926, Dr. Benjamin Sacks and Dr. Emmanuel Libman[3] published cases of "valvular masses" that were examined clinically and during autopsies and found to be free of all microorganisms. These masses were initially named "indeterminate endocarditis".
- In 1936, The name non-bacterial thrombotic endocarditis was coined by Gross and Friedberg. [4]. They postulated that the attachment of fibrin to cardiac valves is the cause of non-bacterial thrombotic endocarditis.
- In recent years it has been suggested that NBTE is a hypercoagulable state caused by a malignancy that leads to a surge in tumor necrosis factor and interleukin-1, resulting in the formation of thrombi.[5]
- More recently, in addition to malignancies, NBTEs have been associated with infectious and autoimmune diseases and more recently, sepsis and burns.[6][7][8]
References
- ↑ Trousseau A. Clinique médicale de l’Hôtel-Dieu de Paris. Paris: Ballière; 1865
- ↑ Lopez JA, Ross RS, Fishbein MC, Siegel RJ (March 1987). "Nonbacterial thrombotic endocarditis: a review". Am. Heart J. 113 (3): 773–84. doi:10.1016/0002-8703(87)90719-8. PMID 3548296.
- ↑ E Ziegler - Ver Kong Inn Med, 1888 - ci.nii.ac.jp
- ↑ GROSS L, FRIEDBERG CK. NONBACTERIAL THROMBOTIC ENDOCARDITIS: CLASSIFICATION AND GENERAL DESCRIPTION. Arch Intern Med (Chic). 1936;58(4):620–640. doi:10.1001/archinte.1936.00170140045004
- ↑ Schlittler LA, Dallagasperina VW, Schavinski C, Baggio AP, Lazaretti NS, Villaroel RU. Marantic endocarditis and adenocarcinoma of unknown primary site. Arq Bras Cardiol. 2011;96(4):e73–5
- ↑ Wada H, Sase T, Yamaguchi M (September 2005). "Hypercoagulant states in malignant lymphoma". Exp. Oncol. 27 (3): 179–85. PMID 16244577.
- ↑ Ferrans VJ, Rodríguez ER (1985). "Cardiovascular lesions in collagen-vascular diseases". Heart Vessels Suppl. 1: 256–61. doi:10.1007/BF02072405. PMID 3916476.
- ↑ Deppisch LM, Fayemi AO (December 1976). "Non-bacterial thrombotic endocarditis: clinicopathologic correlations". Am. Heart J. 92 (6): 723–9. doi:10.1016/s0002-8703(76)80008-7. PMID 998478.